Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.41 |
| ▸ | PPARD | Q03181 | 7/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL465001 | 0.91 | ADORA2A (0.45) | PPARGPPARDADORA2AADORA1ADORA3 | |
| SCHEMBL447288 | 0.87 | ADORA2A (0.49) | PPARGPPARDADORA2AADORA1ADORA3 | |
| SCHEMBL448173 | 0.87 | ADORA2A (0.40) | PPARGPPARDADORA2AADORA1ADORA3 | |
| SCHEMBL450536 | 0.83 | CDK1 (0.45) | ADORA2AADORA1ADORA3AKT1 | |
| SCHEMBL449667 | 0.82 | ADORA2A (0.38) | PPARGPPARDADORA2AADORA1PDE4A | |
| SCHEMBL465000 | 0.81 | CDK1 (0.40) | AKT1 | |
| SCHEMBL7743666 | 0.76 | ADORA3 (0.69) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL7744345 | 0.74 | PDE8A (0.57) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL448638 | 0.71 | CDC7 (0.37) | ADORA2AADORA1ADORA3PDE4APDE4B | |
| SCHEMBL14813260 | 0.70 | HPGD (0.48) | ADORA2AADORA1ADORA3PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557790-B2 | A3 adenoside receptor agonists for the reduction of intraocular pressure | CAN-FITE BIOPHARMA LTD. (IL) | 2013-10-15 | — | — | US | disclosed |
| US-20120065155-A1 | A3 ADENOSIDE RECEPTOR AGONISTS FOR THE REDUCTION OF INTRAOCULAR PRESSURE | CAN-FITE BIOPHARMA LTD. (IL) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065155-A1 | A3 ADENOSIDE RECEPTOR AGONISTS FOR THE REDUCTION OF INTRAOCULAR PRESSURE | ADORA3, ADORA1, ADORA2A | PPARG 2110/4885PPARD 2856/4885ADORA2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.